Ding, Li
Brunaugh, Ashlee D.
Thakkar, Rishi
Lee, Christian
Zhao, Qingyan Jenny
Kalafat, Justin
Maniruzzaman, Mohammed
Smyth, Hugh D. C.
Article History
Received: 29 July 2021
Accepted: 3 November 2021
First Online: 11 January 2022
Declarations
:
: Hugh D. C. Smyth, one of the paper’s authors, works on inhaled product development for Respira Therapeutics, Via Therapeutics, Nob Hill Therapeutics, and Cloxero Therapeutics. The University of Texas at Austin has reviewed and approved the conditions of the agreement in accordance with its research objectivity policy. Ashlee Brunaugh owns stocks in both CloXero Therapeutics and Via Therapeutics companies. The University of Texas at Austin has reviewed and approved the conditions of the agreement in accordance with its research objectivity policy.
Free to read: This content has been made available to all.